HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /PRNewswire/ – ESSA Pharma Inc. (“ESSA” or the “Company”) (Nasdaq: EPIX), a medical-phase pharmaceutical company focused on producing novel therapies for the therapy of prostate cancer, currently introduced that Ari Brettman, M.D., has stepped down from ESSA’s Board of Administrators, which he has been a member of given that 2019. Dr. Brettman is a Handling Director of Blackstone’s Lifetime Science Team and will be assuming a lot more duties in this function.
“We are particularly grateful to Dr. Brettman for his sturdy management and valuable insights as a member of the Board of Directors,” said Richard M. Glickman, Chairman of ESSA’s Board of Administrators. “On behalf of the entire Board and Executive Management Group, I would like to thank Dr. Brettman for his contributions and ongoing support, and we would like him achievement in his upcoming endeavors.”
“It has been an honor to serve on ESSA’s Board and witness the Firm’s great development around the previous few several years,” reported Dr. Brettman. “ESSA’s passionate and skilled administration staff positions the Enterprise for continued good results and I search ahead to next ESSA’s development and the clinical improvement of the lead products applicant, EPI-7386, which has the possible to renovate the remedy paradigm for prostate cancer.”
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical organization centered on building novel and proprietary therapies for the cure of individuals struggling from prostate most cancers. For far more information, be sure to go to www.essapharma.com and abide by us on Twitter below @ESSAPharma.
Ahead-Hunting Assertion Disclaimer
This launch contains specified facts which, as introduced, constitutes “ahead-on the lookout data” inside the which means of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legal guidelines. Forward-looking data involves statements that relate to upcoming occasions and typically addresses predicted future small business and fiscal general performance, that contains terms this kind of as “anticipate”, “think”, “system”, “estimate”, “count on”, and “intend”, statements that an action or celebration “may perhaps”, “may well”, “could”, “should really”, or “will” be taken or arise, or other comparable expressions and features, but is not constrained to, statements concerning the Company’s positioning for good results and development, EPI-7386’s possible to transform the therapy paradigm for prostate cancer and other statements encompassing the Firm’s medical analysis of EPI-7386.
Forward-looking statements and details are topic to a variety of recognised and unidentified challenges and uncertainties, several of which are past the potential of ESSA to management or forecast, and which may perhaps trigger ESSA’s true final results, overall performance or achievements to be materially distinctive from people expressed or implied therefore. These statements replicate ESSA’s current sights with regard to potential gatherings, are issue to risks and uncertainties and are necessarily based mostly upon a number of estimates and assumptions that, while regarded as affordable by ESSA as of the date of these kinds of statements, are inherently issue to important health care, scientific, enterprise, economic, competitive, political and social uncertainties and contingencies. In earning ahead hunting statements, ESSA may make a variety of material assumptions, which include but not confined to (i) the accuracy of ESSA’s monetary projections (ii) obtaining beneficial effects of medical trials (iii) acquiring needed regulatory approvals and (iv) common business enterprise, current market and financial situations.
Ahead-looking information and facts is formulated centered on assumptions about these kinds of threats, uncertainties and other components established out herein and in ESSA’s Annual Report on Variety 10-K dated December 15, 2021 less than the heading “Risk Aspects”, a copy of which is accessible on ESSA’s profile on EDGAR at www.sec.gov, and as if not disclosed from time to time on ESSA’s SEDAR profile www.sedar.com. Forward-seeking statements are designed based on management’s beliefs, estimates and viewpoints on the date that statements are manufactured and ESSA undertakes no obligation to update ahead-looking statements if these beliefs, estimates and viewpoints or other situation really should change, other than as could be demanded by applicable Canadian and United States securities legal guidelines. Visitors are cautioned towards attributing undue certainty to forward-hunting statements.
Watch unique material:https://www.prnewswire.com/news-releases/essa-announces-modify-to-its-board-of-directors-301256925.html
Source ESSA Pharma Inc